GLP-1受体激动剂在1型糖尿病肥胖患者辅助 治疗中的应用研究进展
Research Progress on the Application of GLP-1 Receptor Agonists in the Adjuvant Treatment of Obese Patients with Type 1 Diabetes
摘要: 胰高血糖素样肽-1受体激动剂(Glucagon-Like Peptide-1 Receptor Agonist, GLP-1RAs)通过增加高血糖诱导的胰岛素分泌、抑制高血糖期间胰高血糖素分泌、减慢胃排空、防止餐后血糖大幅增加以及减少热量摄入和体重等机制实现血糖和体重控制。临床上，胰岛素是1型糖尿病患者的核心治疗方法，但胰岛素导致的肥胖会增加1型糖尿病患者心血管疾病和代谢并发症的发生率，例如大动脉粥样硬化和慢性肾病等。近年来，已有临床研究将GLP-1受体激动剂作为1型糖尿病的辅助治疗药物，以协同改善1型糖尿病患者的肥胖率及后续不良事件的发生率。本文系统综述GLP-1RAs在1型糖尿病肥胖患者中的作用机制及临床研究进展，并展望其联合新型疗法的发展潜力。
Abstract: Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RAs) realizes blood sugar and weight control by increasing insulin secretion induced by hyperglycemia, inhibiting glucagon secretion during hyperglycemia, slowing gastric emptying, preventing significant increase in postprandial blood sugar, and reducing calorie intake and weight. In clinical practice, insulin is the core treatment method for type 1 diabetes patients, but obesity caused by insulin will increase the incidence of cardiovascular disease and metabolic complications in type 1 diabetes patients, such as atherosclerosis and chronic kidney disease. In recent years, research has explored GLP-1RAs as an adjuvant treatment drug for type 1 diabetes to synergistically improve the obesity rate of type 1 diabetes patients and the incidence of subsequent adverse events. This article systematically reviews the mechanism and clinical research progress of GLP-1RAs in obese patients with type 1 diabetes, and looks forward to the development potential of its combination with new therapies.
文章引用：周玮洋, 李小丹, 徐家恒, 于照祥. GLP-1受体激动剂在1型糖尿病肥胖患者辅助 治疗中的应用研究进展[J]. 临床医学进展, 2026, 16(4): 774-780. https://doi.org/10.12677/acm.2026.1641306

参考文献

[1] Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B.B., et al. (2022) IDF Diabetes Atlas: Global, Regional and Country-Level Diabetes Prevalence Estimates for 2021 and Projections for 2045. Diabetes Research and Clinical Practice, 183, Article ID: 109119. [Google Scholar] [CrossRef] [PubMed]
[2] Gregory, G.A., Robinson, T.I.G., Linklater, S.E., Wang, F., Colagiuri, S., de Beaufort, C., et al. (2022) Global Incidence, Prevalence, and Mortality of Type 1 Diabetes in 2021 with Projection to 2040: A Modelling Study. The Lancet Diabetes & Endocrinology, 10, 741-760. [Google Scholar] [CrossRef] [PubMed]
[3] Katsarou, A., Gudbjörnsdottir, S., Rawshani, A., Dabelea, D., Bonifacio, E., Anderson, B.J., et al. (2017) Type 1 Diabetes Mellitus. Nature Reviews Disease Primers, 3, Article No. 17016. [Google Scholar] [CrossRef] [PubMed]
[4] Wallace, A.S., Chang, A.R., Shin, J., Reider, J., Echouffo-Tcheugui, J.B., Grams, M.E., et al. (2022) Obesity and Chronic Kidney Disease in US Adults with Type 1 and Type 2 Diabetes Mellitus. The Journal of Clinical Endocrinology & Metabolism, 107, 1247-1256. [Google Scholar] [CrossRef] [PubMed]
[5] The DCCT Research Group (1988) Weight Gain Associated with Intensive Therapy in the Diabetes Control and Complications Trial. Diabetes Care, 11, 567-573. [Google Scholar] [CrossRef] [PubMed]
[6] Yao, H., Zhang, A., Li, D., Wu, Y., Wang, C., Wan, J., et al. (2024) Comparative Effectiveness of GLP-1 Receptor Agonists on Glycaemic Control, Body Weight, and Lipid Profile for Type 2 Diabetes: Systematic Review and Network Meta-Analysis. BMJ, 384, e076410. [Google Scholar] [CrossRef] [PubMed]
[7] Drucker, D.J. (2018) Mechanisms of Action and Therapeutic Application of Glucagon-Like Peptide-1. Cell Metabolism, 27, 740-756. [Google Scholar] [CrossRef] [PubMed]
[8] Foster, N.C., Beck, R.W., Miller, K.M., Clements, M.A., Rickels, M.R., DiMeglio, L.A., et al. (2019) State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. Diabetes Technology & Therapeutics, 21, 66-72. [Google Scholar] [CrossRef] [PubMed]
[9] Cantley, N.W., Lonnen, K., Kyrou, I., Tahrani, A.A. and Kahal, H. (2021) The Association between Overweight/Obesity and Double Diabetes in Adults with Type 1 Diabetes; a Cross-Sectional Study. BMC Endocrine Disorders, 21, Article No. 187. [Google Scholar] [CrossRef] [PubMed]
[10] Donga, E., Dekkers, O.M., Corssmit, E.P.M. and Romijn, J.A. (2015) Insulin Resistance in Patients with Type 1 Diabetes Assessed by Glucose Clamp Studies: Systematic Review and Meta-Analysis. European Journal of Endocrinology, 173, 101-109. [Google Scholar] [CrossRef] [PubMed]
[11] Catalano, K.J., Maddux, B.A., Szary, J., Youngren, J.F., Goldfine, I.D. and Schaufele, F. (2014) Insulin Resistance Induced by Hyperinsulinemia Coincides with a Persistent Alteration at the Insulin Receptor Tyrosine Kinase Domain. PLOS ONE, 9, e108693. [Google Scholar] [CrossRef] [PubMed]
[12] Matteucci, E., Giampietro, O., Covolan, V., Giustarini, D., Fanti, P. and Rossi, R. (2015) Insulin Administration: Present Strategies and Future Directions for a Noninvasive (Possibly More Physiological) Delivery. Drug Design, Development and Therapy, 9, 3109-3118. [Google Scholar] [CrossRef] [PubMed]
[13] Corbin, K.D., Driscoll, K.A., Pratley, R.E., Smith, S.R., Maahs, D.M. and Mayer-Davis, E.J. (2018) Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms. Endocrine Reviews, 39, 629-663. [Google Scholar] [CrossRef] [PubMed]
[14] Petersen, M.C. and Shulman, G.I. (2018) Mechanisms of Insulin Action and Insulin Resistance. Physiological Reviews, 98, 2133-2223. [Google Scholar] [CrossRef] [PubMed]
[15] Buzzetti, R., Zampetti, S. and Pozzilli, P. (2020) Impact of Obesity on the Increasing Incidence of Type 1 Diabetes. Diabetes, Obesity and Metabolism, 22, 1009-1013. [Google Scholar] [CrossRef] [PubMed]
[16] Brooks-Worrell, B.M. and Palmer, J.P. (2019) Setting the Stage for Islet Autoimmunity in Type 2 Diabetes: Obesity-Associated Chronic Systemic Inflammation and Endoplasmic Reticulum (ER) Stress. Diabetes Care, 42, 2338-2346. [Google Scholar] [CrossRef] [PubMed]
[17] Ferrara-Cook, C., Geyer, S.M., Evans-Molina, C., Libman, I.M., Becker, D.J., Gitelman, S.E., et al. (2020) Excess BMI Accelerates Islet Autoimmunity in Older Children and Adolescents. Diabetes Care, 43, 580-587. [Google Scholar] [CrossRef] [PubMed]
[18] Smith, N.K., Hackett, T.A., Galli, A. and Flynn, C.R. (2019) GLP-1: Molecular Mechanisms and Outcomes of a Complex Signaling System. Neurochemistry International, 128, 94-105. [Google Scholar] [CrossRef] [PubMed]
[19] Cho, Y.M., Fujita, Y. and Kieffer, T.J. (2014) Glucagon-Like Peptide-1: Glucose Homeostasis and Beyond. Annual Review of Physiology, 76, 535-559. [Google Scholar] [CrossRef] [PubMed]
[20] American Diabetes Association (2017) 7. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes—2018. Diabetes Care, 41, S65-S72. [Google Scholar] [CrossRef] [PubMed]
[21] Munt, A.E., Partridge, S.R. and Allman‐Farinelli, M. (2016) The Barriers and Enablers of Healthy Eating among Young Adults: A Missing Piece of the Obesity Puzzle: A Scoping Review. Obesity Reviews, 18, 1-17. [Google Scholar] [CrossRef] [PubMed]
[22] Peterson, C.M., Fischer, S. and Young-Hyman, D. (2014) Topical Review: A Comprehensive Risk Model for Disordered Eating in Youth with Type 1 Diabetes. Journal of Pediatric Psychology, 40, 385-390. [Google Scholar] [CrossRef] [PubMed]
[23] Alhadeff, A.L., Mergler, B.D., Zimmer, D.J., Turner, C.A., Reiner, D.J., Schmidt, H.D., et al. (2016) Endogenous Glucagon-Like Peptide-1 Receptor Signaling in the Nucleus Tractus Solitarius Is Required for Food Intake Control. Neuropsychopharmacology, 42, 1471-1479. [Google Scholar] [CrossRef] [PubMed]
[24] Liu, J., Conde, K., Zhang, P., Lilascharoen, V., Xu, Z., Lim, B.K., et al. (2017) Enhanced AMPA Receptor Trafficking Mediates the Anorexigenic Effect of Endogenous Glucagon-Like Peptide-1 in the Paraventricular Hypothalamus. Neuron, 96, 897-909.e5. [Google Scholar] [CrossRef] [PubMed]
[25] Xu, F., Lin, B., Zheng, X., Chen, Z., Cao, H., Xu, H., et al. (2016) GLP-1 Receptor Agonist Promotes Brown Remodelling in Mouse White Adipose Tissue through SIRT1. Diabetologia, 59, 1059-1069. [Google Scholar] [CrossRef] [PubMed]
[26] Marzook, A., Tomas, A. and Jones, B. (2021) The Interplay of Glucagon-Like Peptide-1 Receptor Trafficking and Signalling in Pancreatic Beta Cells. Frontiers in Endocrinology, 12, Article ID: 678055. [Google Scholar] [CrossRef] [PubMed]
[27] Sarkar, G., Alattar, M., Brown, R.J., Quon, M.J., Harlan, D.M. and Rother, K.I. (2014) Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults with Type 1 Diabetes. Diabetes Care, 37, 666-670. [Google Scholar] [CrossRef] [PubMed]
[28] Herold, K.C., Reynolds, J., Dziura, J., Baidal, D., Gaglia, J., Gitelman, S.E., et al. (2020) Exenatide Extended Release in Patients with Type 1 Diabetes with and without Residual Insulin Production. Diabetes, Obesity and Metabolism, 22, 2045-2054. [Google Scholar] [CrossRef] [PubMed]
[29] Rubino, D.M., Greenway, F.L., Khalid, U., O’Neil, P.M., Rosenstock, J., Sørrig, R., et al. (2022) Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults with Overweight or Obesity without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA, 327, 138-150. [Google Scholar] [CrossRef] [PubMed]
[30] Dejgaard, T.F., Schmidt, S., Frandsen, C.S., Vistisen, D., Madsbad, S., Andersen, H.U., et al. (2019) Liraglutide Reduces Hyperglycaemia and Body Weight in Overweight, Dysregulated Insulin‐Pump‐Treated Patients with Type 1 Diabetes: The Lira Pump Trial—A Randomized, Double‐Blinded, Placebo‐Controlled Trial. Diabetes, Obesity and Metabolism, 22, 492-500. [Google Scholar] [CrossRef] [PubMed]
[31] Mathieu, C., Zinman, B., Hemmingsson, J.U., Woo, V., Colman, P., Christiansen, E., et al. (2016) Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-to-Target Randomized Trial. Diabetes Care, 39, 1702-1710. [Google Scholar] [CrossRef] [PubMed]
[32] Ahrén, B., Hirsch, I.B., Pieber, T.R., Mathieu, C., Gómez-Peralta, F., Hansen, T.K., et al. (2016) Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects with Type 1 Diabetes: The ADJUNCT TWO Randomized Trial. Diabetes Care, 39, 1693-1701. [Google Scholar] [CrossRef] [PubMed]
[33] Dhillon, S. (2018) Semaglutide: First Global Approval. Drugs, 78, 275-284. [Google Scholar] [CrossRef] [PubMed]
[34] Garg, S.K., Kaur, G., Haider, Z., Rodriquez, E., Beatson, C. and Snell-Bergeon, J. (2024) Efficacy of Semaglutide in Overweight and Obese Patients with Type 1 Diabetes. Diabetes Technology & Therapeutics, 26, 184-189. [Google Scholar] [CrossRef] [PubMed]
[35] Grassi, B.A., Teresa Onetto, M., Sánchez, C., Tapia, N. and Mena, F. (2024) Effect of Low Dose Semaglutide in People with Type 1 Diabetes and Excess Weight. Diabetes Research and Clinical Practice, 209, Article ID: 111593. [Google Scholar] [CrossRef] [PubMed]
[36] Pasqua, M., Tsoukas, M.A., Kobayati, A., Aboznadah, W., Jafar, A. and Haidar, A. (2025) Subcutaneous Weekly Semaglutide with Automated Insulin Delivery in Type 1 Diabetes: A Double-Blind, Randomized, Crossover Trial. Nature Medicine, 31, 1239-1245. [Google Scholar] [CrossRef] [PubMed]

为你推荐